BCY 2 - Second Breast Cancer in Young Women Conference 4th-5th November 2014 Dublin, Ireland by Burgmann, M. & Wuerstlein, Rachel
Fax +49 761 4 52 07 14
Information@Karger.com
www.karger.com





BCY 2 – Second Breast Cancer in Young Women  
Conference 4th–5th November 2014 Dublin, Ireland
and the importance of improvement of psychosocial and medical 
care of those patients mainly focusing on the US perspective. She 
also focused on the unique aspects of young women with BC. 
They often present an advanced disease because of delays of di-
agnosis (‘you are too young to have breast cancer’) and a more 
aggressive tumor biology (e.g. ER negative, high grade, LVI dis-
ease, HER2-positive). Genetics, fertility and sexuality concerns 
as well as body image and the premenopausal situation play an 
important role in these patients, they need to be understood and 
supported.
Diagnostic tools were presented in the session by M. Sklair-
Levy (IL), who discussed new technologies of breast imaging 
such as tomosynthesis (a modification of digital mammography 
to create 3-dimensional data), contrast-enhanced spectral mam-
mography (CESM), automated breast volume scanner and also 
nuclear breast imaging (positron emission mammography, FDG) 
which are intended to be implemented in the individual diagnosis 
of young breast cancer patients. 
The session on hereditary and familial breast cancer was well 
discussed. E. Levy-Lahad (IL) presented data about the right time 
for genetic testing and discussed issues about rapid genetic test-
ing before initiating any treatment and traditional BRCA-testing 
in the young patient. As genetic testing has a yield of about 25% 
in the young patient, it affects treatment decisions and has there-
fore therapeutic impact. The goal of genetic testing might in any 
case be a treatment-focused genetic testing (TFGT), after diagno-
sis but before surgery. In her talk about local therapy considera-
tions in BRCA1/2 mutation carriers, Ella Evron (IL) showed the 
markedly increased risk of BRCA carriers of contralateral BC and 
presented the design of an initiated Israeli multicenter study on 
the prophylactic contralateral irradiation after breast conserving 
therapy as a potential option of prevention in high-risk patients 
and to reduce the rate of bilateral mastectomy. New systemic 
therapies in hereditary BC were discussed by Judy Garber who 
presented recent data with a neoadjuvant regimen of platinum in 
TNBC (pathologic complete remission (pCR) 61%, Breast Can-
cer Res Treat 2014;147:401–405) as also shown by GEPAR-
SIXTO (higher pCR rates after neoadjuvant anthracycline/taxane 
in TNBC). PARPP inhibitors such as olaparib (Olympia) or nira-
parib (BRAWO) for 1 year after neo-/adjuvant therapy are cur-
rently tested in several protocols as also in combination with 
platinum (carboplatin/gemcitabine/iniparib) in the PrECOG 0105 
scheme. 
Breast cancer (BC) in women under 40 years of age is a com-
plex disease which strikes in a phase of life when young women 
are at the peak of their reproductive years and when family plan-
ning, professional career, and partnership have a lot of impor-
tance. Furthermore, as young women are more likely to have a 
risk of a higher grade and stage of the disease, tumor biology at 
the time of diagnosis and genetic factors play an important role, 
medical treatment and consultation has to be well adapted to the 
needs of this population. So far, little is known about the etiology 
of breast cancer in young women and more research is needed to 
establish an optimal management of these patients. 
The Breast Cancer in Young Women Conference was initiated 
in 2012 by high-ranking breast cancer specialists from Europe, 
Israel, and the US to create a platform about novel research re-
sults, future research concepts and to give the opportunity of net-
working and discussion in this so far poorly researched field. Ad-
ditionally, the first international consensus guidelines for breast 
cancer in young women were developed by international BC 
 specialists, being finally published in June 2014 (Breast 
2014;23:209–220).
Initially planned to take place in Tel Aviv, Israel, BCY 2 was 
changed this year to take place again in Dublin, Ireland because 
of the political conflicts in the Middle East. The BCY 2 confer-
ence was supported and organized by the European School of On-
cology (ESO) (www.eso.net). In 9 sessions and 25 talks in total, 
all ‘hot topics’ around the treatment and diagnosis of young BC 
patients were covered. International speakers gave an overview of 
recent results of breast cancer research, newest developments in 
the treatment of young breast cancer patients and an outlook on 
the results to be presented in San Antonio in December 2014. 
During the conference, the 205 participants from 35 different 
countries heard talks that touched upon tumor biology and pathol-
ogy, genetics, diagnostics, surgery, systemic therapy, radiother-
apy, fertility preservation, and supportive offers.
After the presentation by Bella Kaufmann from the Israel Can-
cer Association (IL), one of the chairs of the conference, BCY 2 
was opened by a field report of a young BC patient. With a very 
personal report, Nicola Elmer (IE) illustrated this intensive and 
difficult phase of her life around the BC diagnosis and all her 
problems during and after systemic therapy, so that a perfect in-
troduction to the conference was given. Ann Partridge (US) con-
tinued in another keynote lecture to refer about the growing popu-
lation of young BC patients, and its relevance for public health 
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In the session about local-regional therapy by O. Gentilini 
(IT), different surgical options for young women with BC and 
also BRCA mutation carriers were discussed, that had become 
more important in the last years with an increasing demand for 
counseling (‘Jolie effect’). As data about the surgical outcome are 
still missing, the surgical treatment should in general be the same 
as in the older patients while in the case of mastectomy immedi-
ate reconstruction should be offered. 
The first day of BYC 2 closed with a special session of Debo-
rah Fenlon (UK) about nursing in younger women with BC and 
the importance of the ‘being there’ for young patients and their 
unique needs and special nursing offers for these patients.
The second day of the conference was opened by K. Gelmon 
(US) about aspects of tumor biology. She once more emphasized 
the higher risk of relapse and worse outcome in younger women 
with BC and the still poorly understood difference of tumor biol-
ogy and its therapy in that special population of patients. 
In the session of systemic therapies, Sybille Loibl (DE) re-
ported data of the NSABP-B18 and B-27 study, which showed a 
better disease free and overall survival for women <50 years after 
neoadjuvant instead of adjuvant chemotherapy. Additionally, 
young women seem to have a higher rate of pCR after being 
treated with an anthracyline and taxane based chemotherapy. In 
that context, Nadia Harbeck (DE) supplemented with data of GE-
PARSIXTO study which showed a higher pCR by adding weekly 
carboplatin to a neoadjuvant treatment in TNBC while in the met-
astatic situation the benefit of platinum is still discussed. As in 
the advanced TNBC, there is still a lack of international chemo-
standards. Professor Harbeck illustrated the importance of current 
clinical trials like the tnAcity trial (nab-paclitaxel/carboplatin ver-
sus nab-paclitaxel/gemcitabine versus carboplatin/gemcitabine) 
to establish a first-line standard in the treatment in the metastatic 
TNBC. In her talk about endocrine therapy, Olivia Pagani (CH) 
gave an update of new endocrine regimens and presented recent 
data about the significant reduction of recurrences by the use of 
aromatase inhibitors plus ovarian function suppression (OFS) as a 
new option in premenopausal (HR+) patients. Also she gave an 
outlook on data about tamoxifen and OFS (SOFT and TEXT 
trial) which were later presented at San Antonio Breast Cancer 
Conference in December 2014. What can be discussed in premen-
opausal and high risk patients is an extended treatment of tamox-
ifen, considering the patient’s life quality. 
As one of the most important issues in young patients, fertility 
and concerns about family planning may play a very important 
role. Shani Paluch-Shimon and Hila Raanani, both from Israel, 
discussed those issues in the next session. Regarding fertility 
preservation, more experience could be made in the last years 
with ovarian tissue cryopreservation and transplantation (first 
successful pregnancy in 2005), also new regimens of stimulation 
before chemo have been developed. Thus, co-administration of 
tamoxifen during stimulation provides safety without affecting 
fertility preservation outcome and can be used in BC patients. 
More data is still needed to handle the desire to have a baby dur-
ing a long-time therapy (endocrine therapy) from the oncological 
perspective. No data exist about the safety of interruption of the 
adjuvant therapy. 
Before the poster session, presentation of the best abstracts 
took place. Thus, Efrat Dagan for research about PGD decisions, 
Matteo Lambertini from Italy with a prospective study about 
pregnancy and fertility, and Megan McCann from the US with 
the development of a toolkit approach for the unique needs of 
young BC patients were honored for their research.
In her talk about advanced breast cancer, Fatima Cardoso (PT), 
chair of the conference, pointed out once more the lack of proven 
standards in the therapy of young BC patients, especially for BRCA 
mutations carriers, and that younger age alone is still no indication 
for a more aggressive therapy. Also she admitted that the young 
patient should undergo the same standards of diagnostic and ther-
apy as the older patients with the same disease in metastatic BC.
The last session of the conference concerned survivorship and 
issues of quality of life. Ann Partridge (US) talked about the real-
ity of oncobrain as a side and long-term effect of our therapies. 
So far, pharmaceutical agents have not been shown to be effec-
tive, settings for cognitive rehabilitation have to be implemented 
in the occupational therapy. Another important but little discussed 
issue is the awareness of achieving life quality after the treatment. 
There is a lack of survivorship care plans or post treatment navi-
gators with recommendations for healthy behaviors, follow-up 
plans for the disease, or just access of medical and psychosocial 
support. E-resources like www.cancer.net/survivorship or www.
ystourdepink.org are examples for such survivorship platforms.
The conference closed with a consensus statement of the lead-
ing international BC specialists to give the base for the second 
consensus guidelines for breast cancer in young women. The 
team of specialist consisted of Fatima Cardoso (PT), Bella Kauf-
mann (IL), Leslie Fallowfield (UK), Deborah Fenlon (UK), 
Karen Gelmon (CA), J Geraghty (IE), Nadia Harbeck (DE), S. 
Higgings (IE), Sybille Loibl (DE), Elizabeth Moser (PT), Olivia 
Pagani (CH), Shani Paluch-Shimon (IL), Ann Partridge (US), 
Fedro Peccatori (IT), and Hila Raanani (IL). 
Panel at the BCY 2 conference, Dublin. 
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In summary, the organizers of BCY 2 provided an excellent 
meeting on this very important topic by inviting the leading ex-
perts for clinical treatment and medical research in young breast 
cancer patient. With selected talks about all different aspects 
within the diagnosis and treatment of the young BC patient, the 
current issues were well reflected. It was emphasized that the hot 
topics in the support of young BC patients are around fertility, 
genetics and that our young patients thus differ significantly from 
postmenopausal patients what has to be well respected in the 
treatment of the young patient. 
As this is the only meeting focused on the young BC patient, it 
renders an excellent platform for networking, discussion, and ex-
change of newest research results in a so far rarely discussed field 
and points out the importance of more research to create an opti-
mal management in the treatment of young women with breast 
cancer. The next meeting will take place in 2016, more informa-
tion can be found at www.eso.net.
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